cerdulatinib cerdulatinib cerdulatinib is a small molecule syk/jak kinase inhibitor in development for treatment of hematological malignancies. it has lowest nm ic50 values against tyk2, jak1, jak2, jak3, fms, and syk. cerdulatinibclinical dataother namesprt062070, prt2070, dmvt-502routes ofadministrationby mouthidentifiers iupac name 4-(cyclopropylamino)-2-pyrimidine-5-carboxamide cas number1198300-79-6 ypubchem cid44595079chemspider32822046 yuniid1lxq45s1ochemical and physical dataformulac20h27n7o3smolar mass445.54 g·mol−13d model (jsmol)interactive image smiles ccs(=o)(=o)n1ccn(cc1)c2=cc=c(c=c2)nc3=nc=c(c(=n3)nc4cc4)c(=o)n inchi inchi=1s/c20h27n7o3s/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14h,2-4,9-12h2,1h3,(h2,21,28)(h2,22,23,24,25) ykey:bglpechzzqdncd-uhfffaoysa-n it is being developed by portola pharmaceuticals; in september 2018 the fda granted orphan drug status to cerdulatinib for the treatment of peripheral t-cell lymphoma (ptcl).